.
MergerLinks Header Logo

Announced

Moderna to acquire OriCiro Genomics for $85m.

Financials

Edit Data
Transaction Value£70m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Majority

Private

Acquisition

Single Bidder

biotechnology company

Cross Border

Japan

Pending

Friendly

Biotechnology

Synopsis

Edit

Moderna, a commercial-stage biotech, agreed to acquire OriCiro Genomics, a developer of a cell-free genome technology, for $85m. "With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing. OriCiro's technology strategically complements our manufacturing expertise and further accelerates our research and development engine. We look forward to welcoming the OriCiro team to Moderna," Stéphane Bancel, Moderna CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US